Join us for ODACon 2022!

The Oncology Data Advisor Supportive Care Summit brings together world-renowned faculty to discuss and debate best practices in oncology supportive care. Untitled design 39 compressedThis year’s event will provide expert perspectives and guidance on evidence-based supportive care for patients receiving novel breast cancer therapies, including the following:

  • Antibody-drug conjugates
  • CDK4/6 inhibitors
  • HER2 tyrosine kinase inhibitors
  • Immune checkpoint inhibitors
  • Monoclonal antibodies
  • PARP inhibitors
  • PI3K inhibitors
  • And more!

Please join us for an exciting and interactive robust online (web and mobile) professional development experience, featuring live video sessions, audience polling with real-time analytics, an interactive community message board, and small group learner-faculty networking sessions.  

Participants may receive 5.5 AMA PRA Category 1 Credit™/MOC Points/ANCC contact hours/ACPE contact hours/ILNA upon completion of the activity evaluation.


Breast cancer is the most common tumor type among women in the United States, accounting for nearly 30% of cancer diagnoses. An estimated 287,850 new cases of invasive breast cancer are reported annually, and 43,250 people die of the disease, making it the second-leading cause of cancer death in women (ACS, 2022a). While earlier detection and the development of novel therapies have expanded treatment options and improved survival in recent years, treatment-related toxicities continue to impact patients’ quality of life (ACS, 2022b). Because toxicities often vary by class of drug prescribed, comprehensive knowledge of each novel therapy class—antibody-drug conjugates, CDK4/6 inhibitors, HER2 tyrosine kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, PARP inhibitors, and PI3 kinase inhibitors—are critical to providing optimal patient-centered care.

In this live symposium, nurse faculty will provide expert perspectives and guidance on the management of patients receiving these novel therapies for breast cancer and will review the mechanisms of action, indications, and efficacy/safety profiles of each class.


Constance Visovsky, PhD, RN, ACNP, FAAN

Chairperson, ODACon 2022
Constance Visovsky, PhD, RN, ACNP, FAAN, is the Director and Leona Hughes Endowed Chair of the College of Nursing at the University of South Florida. She specializes in the treatment of patients with breast cancer, with noted expertise in the management of neurotoxic effects of chemotherapy, particularly chemotherapy-induced peripheral neuropathy. Dr. Visovsky’s research interests include exercise behavior and gait and balance training for improving symptoms of neuropathy in patients receiving chemotherapy for breast cancer. She has authored or coauthored numerous peer-reviewed publications focused on nursing management of patients with cancer.


Abbey Kaler, MS, APRN, FNP-C

Abbey Kaler, MS, APRN, FNP-C, is an Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, where she specializes in the treatment and care of patients with breast cancer. In addition, she is a participator and presenter in the Weekly Advanced Breast Cancer Patient Tumor Board and Educational Webinar Series, and she is Leader of the myCancerConnection and Advanced Breast Cancer Program Partnership at MD Anderson.

Julie LaBarbera, NP

Julia LaBarbera, NP, is a Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, California, where she specializes in the treatment of patients with breast cancer.

Janie Metsker, RN, BSN, CN-BN

Janie Metsker, RN, BSN, CN-BN, is the Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital in Kansas City, Missouri. As a nurse navigator, Ms. Metsker provides support for patients with newly diagnosed and metastatic breast cancer throughout the course of their diagnosis, treatment, and survivorship. In addition, she coordinates two annual retreats for patients with breast cancer and their support systems. 

Schedule of Events




    This activity is supported by independent grants from Gilead Sciences, Inc. and Puma Biotechnology, Inc.

    Copyright © 2022 i3 Health. All rights reserved.